Bnp Paribas Asset Management Holding S.A. Crinetics Pharmaceuticals, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $40.3 Billion
- Q4 2024
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 576,068 shares of CRNX stock, worth $19.9 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
576,068
Previous 491,381
17.23%
Holding current value
$19.9 Million
Previous $25.1 Million
17.3%
% of portfolio
0.07%
Previous 0.06%
Shares
10 transactions
Others Institutions Holding CRNX
# of Institutions
254Shares Held
82.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$314 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$215 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$212 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$187 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$148 Million10.24% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.86B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...